Abstract: |
Precision oncology embodies the targeted and rational treatment of cancer according to the specific molecular alterations underlying an individual patient’s disease. It is now well-established that cancer is primarily a genetic disease caused by inherited and acquired genomic aberrations [1]. Each cancer carries a unique set of “driver” genomic aberrations that work together to promote cancer initiation and maintenance. It is also understood that cancer genomes are inherently unstable, and the accumulation of new driver genomic aberrations can lead to cancer progression and drug resistance [2]. The promise of precision oncology postulates that each cancer can be treated more effectively, and even possibly cured, through understanding and targeting key driver genomic aberrations. This requires first identifying key oncogenic genomic aberrations in cancer cells, enabled via molecular diagnostics, to guide the rational selection of molecular therapeutic agents specifically targeting these alterations. Thus, cancer molecular diagnostics are a fundamental and integral component of precision oncology. © Springer Nature Switzerland AG 2019. |